PT - JOURNAL ARTICLE AU - Ranasinghe, Diyanath AU - Jayathilaka, Deshni AU - Jeewandara, Chandima AU - Gunasinghe, Dumni AU - Ariyaratne, Dinuka AU - Pramanayagam Jayadas, Tibutius Thanesh AU - Kuruppu, Heshan AU - Wijesinghe, Ayesha AU - Bary, Farha AU - Madusanka, Deshan AU - Darshana, Pradeep AU - Guruge, Dinuka AU - Wijayamuni, Ruwan AU - Ogg, Graham S. AU - Malavige, Gathsaurie Neelika TI - Molecular epidemiology of AY.28 and AY.104 delta sub-lineages in Sri Lanka AID - 10.1101/2022.02.05.22270436 DP - 2022 Jan 01 TA - medRxiv PG - 2022.02.05.22270436 4099 - http://medrxiv.org/content/early/2022/02/07/2022.02.05.22270436.short 4100 - http://medrxiv.org/content/early/2022/02/07/2022.02.05.22270436.full AB - Background The worst SARS-CoV-2 outbreak in Sri Lanka was due to the two Sri Lankan delta sub-lineages AY.28 and AY.104. We proceeded to further characterize the mutations and clinical disease severity of these two sub-lineages.Methods 705 delta SARS-CoV-2 genomes sequenced by our laboratory from mid-May to November 2021 using Illumina and Oxford Nanopore were included in the analysis. The clinical disease severity of 440/705 individuals were further analyzed to determine if infection with either AY.28 or AY.104 was associated with more severe disease. Sub-genomic RNA (sg-RNA) expression was analyzed using periscope.Results AY.28 was the dominant variant throughout the outbreak, accounting for 67.7% of infections during the peak of the outbreak. AY.28 had three lineage defining mutations in the spike protein: A222V (92.80%), A701S (88.06%), and A1078S (92.04%) and seven in the ORF1a: R24C, K634N, P1640L, A2994V, A3209V, V3718A, and T3750I. AY.104 was characterized by the high prevalence of T95I (90.81%) and T572L (65.01%) mutations in the spike protein and by the absence of P1640L (94.28%) in ORF1a with the presence of A1918V (98.58%) mutation. The mean sgRNA expression levels of ORF6 in AY.28 were significantly higher compared to AY.104 (p < 0.0001) and B.1.617.2 (p < 0.01). Also, ORF3a showed significantly higher sgRNA expression in AY.28 compared to AY.104 (p < 0.0001). There was no difference in the clinical disease severity or duration of hospitalization in individuals infected with these sub lineages.Conclusions Therefore, AY.28 appears to have a fitness advantage over the parental delta variant (B.1.617.2) and AY.104 possibly due to the A222V mutation. AY.28 also had a higher expression of sg-RNA compared to other sub-lineages. The clinical implications of these should be further investigated.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWorld Health Organization; World bank, Sri Lanka Covid 19 Emergency Response and Health Systems Preparedness Project (ERHSP) of Ministry of Health Sri Lanka funded by World Bank.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was obtained from the Ethics Review Committee of University of Sri Jayewardenepura, Sri Lanka.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available in the manuscript and the supporting files.